Evidence map›Paper›PMID 29429559›Full record

ArticleBrain & development2018

EPO improved neurologic outcome in rat pups late after traumatic brain injury.

Michelle E Schober, Daniela F Requena, Christopher K Rodesch

Abstract read
In one paragraph

Article in Brain & development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michelle E SchoberDepartment of Pediatrics, Division of Critical Care, University of Utah, Salt Lake City, UT 84132, United States. Electronic address: michelle.schober@hsc.utah.edu.
Daniela F RequenaDepartment of Pediatrics, Division of Critical Care, University of Utah, Salt Lake City, UT 84132, United States.
Christopher K RodeschCore Facilities and Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, UT 84132, United States.
University of Utah · US

Funding

Genetic /Developmental Mechanisms of Pediatric DiseasesK12HD001410 · NICHD · UNIVERSITY OF UTAH · PI CLARK, EDWARD BOWERSOX · 2003 to 2012
$4.3M
NICHD NIH HHS K12 HD001410
6 · The paper itself

Abstract

In adult rats, erythropoietin improved outcomes early and late after traumatic brain injury, associated with increased levels of Brain Derived Neurotrophic Factor. Using our model of pediatric traumatic brain injury, controlled cortical impact in 17-day old rats, we previously showed that erythropoietin increased hippocampal neuronal fraction in the first two days after injury. Erythropoietin also decreased activation of caspase3, an apoptotic enzyme modulated by Brain Derived Neurotrophic Factor, and improved Novel Object Recognition testing 14 days after injury. Data on long-term effects of erythropoietin on Brain Derived Neurotrophic Factor expression, histology and cognitive function after developmental traumatic brain injury are lacking. We hypothesized that erythropoietin would increase Brain Derived Neurotrophic Factor and improve long-term object recognition in rat pups after controlled cortical impact, associated with increased neuronal fraction in the hippocampus.

methodsRats pups received erythropoietin or vehicle at 1, 24, and 48 h and 7 days after injury or sham surgery followed by histology at 35 days, Novel Object Recognition testing at adulthood, and Brain Derived Neurotrophic Factor measurements early and late after injury.

resultsErythropoietin improved Novel Object Recognition performance and preserved hippocampal volume, but not neuronal fraction, late after injury.

conclusionsImproved object recognition in erythropoietin treated rats was associated with preserved hippocampal volume late after traumatic brain injury. Erythropoietin is approved to treat various pediatric conditions. Coupled with exciting experimental and clinical studies suggesting it is beneficial after neonatal hypoxic ischemic brain injury, our preliminary findings support further study of erythropoietin use after developmental traumatic brain injury.

Indexed as

AnimalsAnimals, NewbornBrain-Derived Neurotrophic FactorBrain Injuries, TraumaticCognitionErythropoietinHippocampusMaleMaze LearningModels, AnimalNeuronsRatsRats, Sprague-DawleyBrain-Derived Neurotrophic FactorErythropoietinerythropoietin, ratApoptosisControlled cortical impactDevelopmentalErythropoietinNeurocognitive impairment

Identifiers

PMID29429559
PMCPMC5878733
OpenAlexW2789391164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.